As of Mar 30
| -0.01 / -0.69%|
The 6 analysts offering 12-month price forecasts for TCR2 Therapeutics Inc have a median target of 2.00, with a high estimate of 3.00 and a low estimate of 1.68. The median estimate represents a +38.89% increase from the last price of 1.44.
The current consensus among 7 polled investment analysts is to Hold stock in TCR2 Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.